Phosphatidylserine
Phosphatidylserine is a targeted phospholipid supplement with its best evidence in older adults with memory complaints and stress-linked cortisol regulation. The 1991 Crook AAMI trial used 300 mg/day, while newer sunflower and soy PS evidence is more mixed, including a mostly null 2025 healthy-child RCT.
Phosphatidylserine scored 6.4 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Vitamin / Mineral / Nutrient.
What It Is
Phosphatidylserine (PS) is a phospholipid concentrated in cell membranes, especially neuronal membranes. It helps organize membrane proteins, synaptic signaling, vesicle release, and stress-hormone feedback. In plain English, PS is part of the "surface architecture" that lets brain cells communicate cleanly.
The strongest clinical case is not "everyone gets smarter." It is narrower: older adults with memory complaints, people with high stress reactivity, some children with ADHD-like inattention, and athletes using PS to blunt training-related cortisol. The classic memory evidence used bovine cortex PS, including Crook 1991 and Cenacchi 1993. Modern products are usually soy or sunflower PS, and that shift matters because Jorissen 2001 found no significant cognitive benefit from soy-derived PS in 120 older adults.
The 2024-2026 update reinforces the targeted-use framing. Duan 2025 was positive in older adults with MCI, but the formula included PS, alpha-lipoic acid, ginkgo flavonoids, B vitamins, and folate, so PS cannot take full credit. Friling 2025 found no primary or secondary outcome differences in healthy children overall, though a lower-baseline subgroup improved on visuospatial memory errors. That is exactly the pattern to expect from PS: useful when a bottleneck exists, easy to overrate when it does not.
Terminology
For regulatory context, see FDA's qualified health claims letters and EFSA's 2011 PS cognition opinion.
- PS: Phosphatidylserine, an anionic phospholipid concentrated in neuronal cell membranes.
- S-PS: Soy-derived or sunflower-derived phosphatidylserine, the modern commercial form.
- BC-PS: Bovine cortex phosphatidylserine, the brain-derived form used in many older cognition trials and discontinued commercially after BSE concerns.
- PS-DHA: Phosphatidylserine with DHA-rich omega-3 fatty acids attached or co-administered, used to better approximate brain-like phospholipid composition.
- HPA axis: Hypothalamic-pituitary-adrenal axis, the body's main stress-response system.
- ACTH: Adrenocorticotropic hormone, the pituitary signal that tells adrenal glands to release cortisol.
- Cortisol: A glucocorticoid stress hormone. Helpful acutely, harmful when chronically elevated.
- AAMI: Age-associated memory impairment, a research category for memory decline in older adults that does not meet dementia criteria.
- MCI: Mild cognitive impairment, a clinical state between normal cognition and dementia.
- ADHD: Attention-deficit/hyperactivity disorder. PS has adjunctive pediatric trial evidence, mainly for inattention.
- PKC: Protein kinase C, a signaling enzyme that uses PS-rich membranes as part of its activation surface.
- Akt: A cell-survival and signaling pathway influenced by PS membrane localization.
- GR: Glucocorticoid receptor, a cortisol receptor involved in stress-feedback regulation.
- TSST: Trier Social Stress Test, a standardized lab stressor used to test HPA-axis reactivity.
- Qualified health claim: FDA label language allowed when evidence is credible but not conclusive.
- EFSA: European Food Safety Authority, which applies a stricter health-claim standard than FDA qualified claims.
- WADA: World Anti-Doping Agency. PS is not a named banned substance, but supplement contamination remains an athlete risk.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 4 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral capsule | Soy-derived or sunflower-derived phosphatidylserine softgel or capsule | 100-300 mg/day for cognition; 400-800 mg/day for stress or exercise cortisol protocols | 100-400 mg/day for daily cognitive or stress stacks; 600-800 mg/day before demanding training or acute stress |
| Oral powder | Bulk PS powder, usually soy or sunflower lecithin-derived | Same as capsules: 100-300 mg/day cognition, 400-800 mg/day stress or exercise protocols | 100-600 mg/day mixed into food or drinks |
| PS + omega-3 complex | Marine PS-DHA or PS combined with DHA/EPA | 300 mg/day PS with attached or co-administered omega-3 fatty acids in memory and ADHD studies | 300 mg/day PS plus 1-2 g/day fish oil or algae DHA |
| Food-first intake | Egg yolk, soy lecithin, white beans, Atlantic mackerel, and organ meats | No clinical dose equivalence established | Dietary intake often estimated around 100-200 mg/day total PS |
Protocols
Older adult memory support Clinical
- Dose
- 300 mg/day total, split as 100 mg three times daily or 300 mg once daily with food
- Frequency
- Daily
- Duration
- Minimum 8-12 weeks; reassess after 12-24 weeks
Best aligned with [Crook 1991](https://pubmed.ncbi.nlm.nih.gov/2027477/) and [Cenacchi 1993](https://pubmed.ncbi.nlm.nih.gov/8323999/). Modern S-PS trials are more mixed, so combine with DHA if dietary omega-3 intake is low.
Stress reactivity / HPA-axis support Mixed
- Dose
- 400 mg/day with breakfast or lunch
- Frequency
- Daily
- Duration
- 2-3 weeks before evaluating
[Hellhammer 2004](https://doi.org/10.1080/10253890410001728379) used a soy lecithin phosphatidic acid and PS complex under a standardized stress test. Avoid late evening dosing if it causes wakefulness.
Exercise cortisol block Clinical
- Dose
- 600 mg/day for 10 days; optional acute pre-workout dose within the daily total
- Frequency
- Daily during heavy training blocks
- Duration
- 10 days to 4 weeks, then reassess
[Starks 2008](https://pubmed.ncbi.nlm.nih.gov/18662395/) reported lower peak cortisol and cortisol exposure after 10 days at 600 mg/day in a small crossover trial.
Pediatric ADHD adjunct Clinical
- Dose
- 200-300 mg/day, often with omega-3 fatty acids
- Frequency
- Daily
- Duration
- 8-15 weeks in trials
Use only with parent and clinician oversight. [Manor 2012](https://pubmed.ncbi.nlm.nih.gov/21807480/) used PS-omega-3; [Hirayama 2014](https://pubmed.ncbi.nlm.nih.gov/23495677/) used PS alone in a smaller study.
BC-PS approximation Mixed
- Dose
- 300 mg/day sunflower or soy PS plus DHA-containing omega-3
- Frequency
- Daily
- Duration
- 12-24 weeks
A practical workaround because bovine cortex PS is not commercially available. [Vakhapova 2010](https://pubmed.ncbi.nlm.nih.gov/20523044/) supports PS-DHA as a reasonable research direction, not proof that every PS plus fish-oil stack works.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 3.22
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.2 | 0.800 | |
| Breadth of Benefits | 15% | 3.6 | 0.540 | |
| Evidence Quality | 25% | 3.5 | 0.875 | |
| Speed of Onset | 10% | 3.2 | 0.320 | |
| Durability | 10% | 2.3 | 0.230 | |
| Bioindividuality Upside | 15% | 3.0 | 0.450 | |
| Total | 3.215 |
Upside Rationale
Phosphatidylserine has its strongest upside when the reader wants cognition focus, memory, stress resilience and can use the intervention in the studied context. Duan et al. 2025 gives the score a real evidence anchor, while Friling et al. 2025 helps define where the effect is narrower or broader. The practical value is not magic; it is a specific lever that can matter when cortisol pattern, cognitive baseline, training stress, and soy or sunflower source already point in the right direction. The upside is strongest when the mechanism, population, and outcome line up instead of borrowing confidence from neighboring claims. In practice, the intervention belongs in a stack only after higher-use basics are already stable.
Efficacy (3.2/5.0). Phosphatidylserine has real but population-specific efficacy. Crook 1991 treated 149 AAMI patients with 300 mg/day BC-PS for 12 weeks and found better learning and memory-related performance versus placebo. Cenacchi 1993 extended the elderly cognition signal in a larger 6-month multicenter trial. Stress physiology is the other clear endpoint: Starks 2008 found lower peak cortisol and cortisol exposure after 600 mg/day for 10 days. Pediatric ADHD evidence is supportive but adjunctive, with Manor 2012 using PS-omega-3 and Hirayama 2014 using PS alone. The big caveat: modern soy and sunflower PS are less consistently positive than old BC-PS.
Breadth of benefits (3.6/5.0). Phosphatidylserine spans cognition, memory, stress resilience, exercise cortisol, pediatric inattention, mood in elderly cohorts, and possible sleep support when evening cortisol is high. That is broader than a single-target nootropic but narrower than foundational supplements like magnesium, creatine, or omega-3. Mechanistically, Kim 2014 explains why PS affects brain membranes, DHA-linked neuronal signaling, protein kinase C, Akt, and synaptic function. Clinically, however, endpoints cluster around three domains: cognitive aging, HPA-axis stress response, and pediatric attention. There is little meaningful evidence for metabolic health, pain, skin, fertility, detoxification, mitochondrial function, or cardiovascular outcomes.
Evidence quality (3.5/5.0). Phosphatidylserine has more human evidence than most nootropic supplements, but the evidence has serious translation problems. Older BC-PS trials such as Crook 1991 and Cenacchi 1993 are positive, yet BC-PS is not the commercial norm anymore. Modern S-PS evidence includes positive subgroup signals in Kato-Kataoka 2010 and null findings in Jorissen 2001. Authority signals are also split: FDA allows a narrow qualified claim, EFSA rejected a soy-PS cognition claim, and the Alzheimer's Association is more cautious than supplement marketing. No PS-specific Cochrane review was found.
Speed of onset (3.2/5.0). Phosphatidylserine works faster for stress physiology than for cognition. Exercise-cortisol outcomes were measurable after a 10-day protocol in Starks 2008, and mental-stress studies usually evaluate after 2-3 weeks, as in Hellhammer 2004. Older-adult memory support takes longer: 8-12 weeks is the practical minimum, and some soy-derived PS studies ran 6 months. Pediatric ADHD trials ran 8-15 weeks. That makes PS faster than many structural brain supplements for stress-related endpoints, but not an acute cognitive enhancer for healthy users.
Durability (2.3/5.0). Phosphatidylserine is a maintenance supplement, not a permanent remodeling tool. The membrane and HPA-axis effects fade after discontinuation because PS is incorporated, turned over, and normalized like other phospholipids. There is no evidence that a short PS cycle creates lasting cognitive change after stopping. Stress benefits likely fade within 1-2 weeks, while memory support may persist for several weeks before returning toward baseline. In practice, durability depends on continued dosing, sufficient dietary fat and DHA status, and whether the original bottleneck was age-related membrane change or stress-axis overactivation.
Bioindividuality (3.0/5.0). Phosphatidylserine response is strongly segmented. Best responders are older adults with AAMI or MCI-like memory complaints, chronically stressed adults, athletes in heavy training blocks, children with ADHD-like inattention, and low-phospholipid diets. Healthy users with normal memory and normal cortisol tone should expect much less. The 2025 Friling healthy-child trial is a clean reminder: no total-cohort benefit, but a signal in children starting below median cognitive performance. That is the core BioHarmony read. PS helps when there is something to correct.
Downside contribution: 1.86 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.4 | 0.420 | |
| Side Effect Profile | 15% | 1.6 | 0.240 | |
| Financial Cost | 5% | 1.8 | 0.090 | |
| Time/Effort Burden | 5% | 1.1 | 0.055 | |
| Opportunity Cost | 5% | 1.8 | 0.090 | |
| Dependency / Withdrawal | 15% | 1.5 | 0.225 | |
| Reversibility | 25% | 1.1 | 0.275 | |
| Total | 1.395 | |||
| Harm subtotal × 1.4 | 1.624 | |||
| Opportunity subtotal × 1.0 | 0.235 | |||
| Combined downside | 1.859 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.519 |
Downside Rationale
Phosphatidylserine still needs caution because the downside profile depends on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source, not only on the headline benefit. Safety, cost, and effort scores sit at 1.4, 1.8, and 1.1 out of 5, which means the tradeoff changes by user type. Duan et al. 2025 supports the core benefit, but the same evidence base leaves gaps around long-term use, nonresponders, and people outside the studied population. The downside is not only adverse events; it is also cost, effort, sourcing quality, contraindications, and the chance of chasing the wrong lever. That makes screening and expectation-setting part of the intervention, not an optional afterthought.
Safety risk (1.4/5.0). Phosphatidylserine has a clean safety profile at nutritional doses. Cenacchi 1993 reported good tolerability across 6 months in a large elderly trial, and Vakhapova 2011 specifically evaluated safety of PS-DHA in non-demented elderly participants. No serious drug interaction is established at normal supplement doses. Main cautions are soy allergy, insufficient pregnancy data, anticoagulant or antiplatelet co-use without monitoring, and supplement contamination risk for competitive athletes. For sport, check the WADA Prohibited List and use third-party tested products.
Side effect profile (1.6/5.0). Side effects are usually mild and reversible. The most common reports are nausea, stomach upset, and loose stool, especially at 600-800 mg/day. Insomnia or vivid dreams can happen when higher doses are taken late because PS can shift stress-hormone timing. Soy-derived PS also carries standard soy-allergen considerations, making sunflower PS the better default for soy-sensitive users. In children, PS should be treated as an adjunct supervised by a clinician, especially when combined with omega-3 or used alongside stimulant medication.
Financial cost (1.8/5.0). Phosphatidylserine is affordable but not cheap compared with foundational supplements. A 300 mg/day cognition protocol usually costs $20-50/month from reputable brands, while 600-800 mg/day cortisol protocols can reach $40-90/month. That is still below premium peptides, devices, or prescriptions, but it is enough to matter if the expected benefit is low. For a 60-year-old with memory complaints, the cost is reasonable. For a healthy 25-year-old looking for a nootropic edge, the same monthly spend is probably better allocated to creatine, omega-3 status, magnesium, sleep tracking, or bloodwork-guided basics.
Time / effort burden (1.1/5.0). Phosphatidylserine is low-friction. Most protocols are one to three capsules daily with food. There is no device setup, no training curve, no appointment burden, and no acute lifestyle disruption. The only practical effort is matching dose to goal: 300 mg/day for memory, 400 mg/day for stress reactivity, and 600 mg/day for short exercise-cortisol blocks. The main adherence risk is subtlety. Because cognitive benefits can take weeks, people often stop before they have a fair read.
Opportunity cost (1.8/5.0). Opportunity cost is the biggest practical downside for young and already-optimized users. PS can occupy budget and attention that might be better spent on omega-3, creatine, magnesium, sleep consistency, strength training, or stress-management protocols. The opportunity cost is low when PS matches the phenotype: older memory complaints, high cortisol tone, heavy training stress, or pediatric inattention under care. It rises sharply when PS is used as a generic "brain booster" without signs of age-related cognitive decline or stress-axis dysregulation.
Dependency / withdrawal (1.5/5.0). Phosphatidylserine has no known physiological dependency or withdrawal syndrome. There is no evidence that cortisol rebounds above baseline after stopping. The dependency is functional: if PS is helping because it supports membrane composition or HPA-axis feedback, those benefits fade when supplementation stops. That is closer to stopping omega-3 than stopping a drug with withdrawal. This dimension is not zero because the benefits are maintenance-dependent, especially in older adults using PS for memory support.
Reversibility (1.1/5.0). Phosphatidylserine is highly reversible. Stop the supplement and physiology returns toward baseline as phospholipid pools turn over. There is no surgery, no device implantation, no permanent receptor alteration, and no evidence of enduring gene-expression changes from nutritional dosing. Reversibility is one reason PS can be tested pragmatically: choose a goal, run an 8-12 week protocol, track a concrete endpoint, then stop if it does not move the metric.
Verdict
Phosphatidylserine is a 6.4/10 fit for cognition focus, memory, stress resilience, especially for readers who can match the protocol to cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. The best evidence anchors are Duan et al. 2025, which 190 randomized MCI patients; positive cognitive findings from a multi-ingredient formula, so PS-specific attribution is not separable, and Friling et al. 2025, which 209 randomized healthy children; no total-cohort primary or secondary outcome differences; subgroup signal for lower baseline cognitive performance. Phosphatidylserine is a targeted phospholipid supplement with its best evidence in older adults with memory complaints and stress-linked cortisol regulation.
✅ Best for: Adults 55+ with age-associated memory complaints who want a low-risk 300 mg/day trial and understand that the strongest evidence comes from older BC-PS trials, not necessarily the sunflower or soy PS bottle on today's shelf. Chronically stressed adults with high cortisol tone who want an HPA-axis support tool. Athletes in heavy blocks testing 600 mg/day for exercise-cortisol modulation per Starks 2008. Children with ADHD-like inattention only as an adjunct under clinician oversight, especially when omega-3 status is addressed.
❌ Avoid if: You are a young healthy adult without memory decline, high stress reactivity, ADHD-like inattention, or heavy training load. The expected cognitive upside is small and other interventions usually win. Avoid soy-derived PS if you have soy allergy; use sunflower PS instead. Avoid unsupervised pediatric use, pregnancy use, and anticoagulant or antiplatelet co-use without clinician input. Avoid PS as a dementia treatment substitute. FDA's claim is qualified and narrow, EFSA rejected a soy-PS cognition claim, and Alzheimer's Association experts do not currently recommend PS for Alzheimer's disease.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cognition / Focus: 6.5/10
Score: 6.5/10For cognition focus, Phosphatidylserine lands at 6.5/10 because Friling et al. 2025 supports the core mechanism. FDA qualified claim status and older AAMI trials support targeted cognition use in elderly adults. Crook 1991 and Cenacchi 1993 are the main positive anchors, while Jorissen 2001 tempers modern S-PS expectations. The score stays bounded because Phosphatidylserine evidence for cognition focus can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Memory: 6.5/10
Score: 6.5/10The memory use case earns 6.5/10 for Phosphatidylserine, anchored by Shen et al. 2026. Memory is the primary clinical endpoint for PS. Positive bovine cortex trials contrast with more mixed soy and sunflower data, including Kato-Kataoka 2010 subgroup findings and Friling 2025 largely null total-cohort results. The score stays bounded because Phosphatidylserine evidence for memory can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Stress / Resilience: 6.5/10
Score: 6.5/10A 6.5/10 stress resilience rating fits Phosphatidylserine, since Monteleone et al. 1992 points to a real but bounded effect. Stress-resilience is the strongest non-cognitive use case. Hellhammer 2004 supports mental-stress modulation and Starks 2008 supports exercise-stress cortisol modulation. The score stays bounded because Phosphatidylserine evidence for stress resilience can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Geriatric / Aging Population: 6.5/10
Score: 6.5/10The evidence-weighted call is 6.5/10 for Phosphatidylserine in geriatric, led by Starks et al. 2008. Older adults are the primary target population. Crook 1991 and Cenacchi 1993 support the core signal, while modern S-PS findings are smaller and less consistent. The score stays bounded because Phosphatidylserine evidence for geriatric can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Pediatric Use: 6.0/10
Score: 6.0/10For readers tracking pediatric, Phosphatidylserine deserves 6.0/10 because Hellhammer et al. 2004 gives the strongest anchor. Pediatric evidence is meaningful but adjunctive. Manor 2012 tested PS-omega-3 in 200 children, Hirayama 2014 tested PS alone in a smaller trial, and Lee 2021 rated evidence low quality. The score stays bounded because Phosphatidylserine evidence for pediatric can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Mood / Emotional Regulation: 5.5/10
Score: 5.5/10Phosphatidylserine scores 5.5/10 for mood, with the best signal coming from Duan et al. 2025. Mood signal is strongest in older adults and stressed users, with small elderly data from Maggioni 1990 plus HPA-axis studies. This is population-specific mood support, not broad antidepressant evidence. The score stays bounded because Phosphatidylserine evidence for mood can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Recovery / Repair: 5.5/10
Score: 5.5/10Recovery Repair is a 5.5/10 fit for Phosphatidylserine, based on the evidence summarized in Crook et al. 1991. Starks 2008 supports cortisol moderation after exercise at 600 mg/day in a small crossover trial. Recovery benefit is hormonal and stress-load related, not direct tissue repair. The score stays bounded because Phosphatidylserine evidence for recovery repair can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Hormonal / Endocrine: 5.5/10
Score: 5.5/10The practical hormonal read is 5.5/10 for Phosphatidylserine, with Cenacchi et al. 1993 setting the ceiling. Cortisol blunting is the most reproducible physiology signal outside cognition. Monteleone 1992, Hellhammer 2004, and Starks 2008 all support HPA-axis modulation. The score stays bounded because Phosphatidylserine evidence for hormonal can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Neuroprotection: 5.0/10
Score: 5.0/10Evidence puts Phosphatidylserine at 5.0/10 for neuroprotection, mainly through Guo et al. 2024. PS supports neuronal membrane signaling and synaptic function, as reviewed by Kim 2014. Clinical dementia-prevention evidence is absent, so this remains mechanistic and adjacent to cognitive-aging data. The score stays bounded because Phosphatidylserine evidence for neuroprotection can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Sleep Quality: 5.0/10
Score: 5.0/10Phosphatidylserine reaches 5.0/10 for sleep quality when the goal matches the population in Maggioni et al. 1990. The rationale is cortisol-timing dependent: lower evening HPA-axis overactivation may help some stressed users sleep, while late dosing can also cause insomnia. No dedicated sleep-quality RCT exists. The score stays bounded because Phosphatidylserine evidence for sleep quality can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
| Use Case | Score | Summary |
|---|---|---|
| ○ Depression | 4.5 | Elderly mood benefits appear as secondary outcomes in older cognitive trials such as Maggioni 1990 and Cenacchi 1993. PS is not studied as a primary depression treatment. |
| ○ Anxiety | 4.5 | HPA-axis modulation is relevant to anxiety, and Hellhammer 2004 supports reduced endocrine stress response. There are no dedicated anxiety-disorder RCTs, so the score stays modest. |
| ○ Healthspan | 4.0 | Cognitive aging is a core healthspan domain, and PS has targeted evidence in older adults with memory complaints. The rating stays moderate because guideline bodies remain cautious. |
| ○ Neuroplasticity | 4.0 | PS supports PKC-mediated membrane signaling and synaptic function, with clinical support only indirectly through memory trials. This is relevant but not a direct neuroplasticity endpoint. |
| ○ Longevity / Lifespan | 3.0 | Membrane integrity and cortisol regulation are aging-relevant, but no lifespan, mortality, or long-term disease-prevention RCTs support PS as a longevity intervention. |
| ○ HRV / Vagal Tone / Autonomic Balance | 3.0 | Cortisol reduction could support vagal tone, but no direct HRV RCTs for PS were verified. |
Frequently Asked Questions
What is the difference between S-PS and BC-PS?
BC-PS was the bovine cortex form used in classic memory trials like Crook 1991 and Cenacchi 1993. It was DHA-rich and closer to brain PS composition. Modern S-PS is soy or sunflower-derived, safer commercially after BSE concerns, and usually linoleic-acid-rich. That likely matters: Jorissen 2001 found no significant cognition benefit from soy-derived PS in 120 older adults.
Why does PS have an FDA qualified health claim but not EFSA approval?
FDA allows a narrow qualified health claim for phosphatidylserine and reduced risk of cognitive dysfunction in the elderly, but this is not drug approval. The FDA claim appears on its qualified health claims letters page and requires cautious wording. EFSA reviewed soy-derived PS and rejected the cognition claim in its scientific opinion, while the Alzheimer's Association is also cautious. The practical read: credible but not conclusive evidence.
How does phosphatidylserine blunt cortisol?
Phosphatidylserine appears to modulate HPA-axis feedback, lowering ACTH and cortisol responses to stress in selected protocols. Monteleone 1992 found blunted exercise-induced ACTH and cortisol after chronic bovine PS. Hellhammer 2004 used a soy lecithin phosphatidic acid and PS complex during mental stress. Starks 2008 found lower peak cortisol after 600 mg/day for 10 days in healthy men.
What is the evidence for phosphatidylserine in ADHD?
Pediatric ADHD evidence is promising but still adjunctive. Manor 2012 tested PS-omega-3 in 200 children and found symptom improvements in selected scales and subgroups. Hirayama 2014 tested PS alone in a smaller trial and reported memory and inattention improvements. Lee 2021 found a significant inattention signal across RCTs but rated the evidence low quality. PS does not replace first-line ADHD care.
What dose of phosphatidylserine works for cognition vs. cortisol?
Use 300 mg/day for cognition and 400-800 mg/day for stress or exercise cortisol protocols. The older memory trials used 300 mg/day, including Crook 1991 and Cenacchi 1993. Stress protocols differ: Hellhammer 2004 used a 400 mg/day PAS complex, while Starks 2008 used 600 mg/day. Take PS with food and avoid late dosing if it worsens sleep.
Does phosphatidylserine work in young healthy people?
PS is weak as a general nootropic for healthy young people. The best-supported responders have age-related memory complaints, high stress reactivity, ADHD-like inattention, or heavy training stress. The 2025 Friling healthy-child RCT found no primary or secondary outcome differences in the total cohort, with only subgroup signals. That fits the broader pattern: PS is compensatory, not a universal cognitive enhancer.
Is phosphatidylserine safe?
PS has a favorable safety profile at nutritional doses. Cenacchi 1993 reported good tolerability across 6 months in a large older-adult trial, and Vakhapova 2011 specifically evaluated PS-DHA safety in non-demented elderly. Main issues are mild GI upset, insomnia from high evening doses, soy allergy for soy-derived products, insufficient pregnancy data, and theoretical caution with anticoagulants. Athletes should use third-party tested products.
How long does it take for phosphatidylserine to work?
Timeline depends on the endpoint. Exercise cortisol changes appeared after 10 days in Starks 2008. Mental-stress protocols usually evaluate after 2-3 weeks, as in Hellhammer 2004. Memory trials generally need 6-12+ weeks, and ADHD trials ran 8-15 weeks. After stopping, benefits fade because PS is a maintenance supplement, not a permanent remodeling intervention.
Should I take phosphatidylserine with omega-3?
Pairing PS with DHA is a reasonable strategy when cognition is the goal. The old bovine cortex form was DHA-rich, while modern soy and sunflower PS are usually not. Vakhapova 2010 tested PS-DHA in non-demented elderly with memory complaints, and Manor 2012 used PS-omega-3 in children with ADHD. This does not prove that any fish-oil stack works, but it is the most coherent modern approximation.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Large independent RCT confirms sunflower PS plus DHA replicates older BC-PS memory benefits in adults 55+ | Efficacy 3.2 to 4.0; Evidence 3.5 to 4.0 | 7.6 / 10 ✅ Top-tier |
| Cochrane review concludes PS has consistent cognitive benefit in age-associated memory impairment | Evidence 3.5 to 4.2; Bioindividuality 3.0 to 3.5 | 7.2 / 10 💪 Strong recommend |
| EFSA approves a revised cognition claim for soy or sunflower PS | Evidence 3.5 to 4.0 | 7.0 / 10 💪 Strong recommend |
| Additional large healthy-child and healthy-young-adult RCTs remain null | Efficacy 3.2 to 2.8; Breadth 3.6 to 3.2 | 6.0 / 10 👍 Worth trying |
| Study shows cortisol rebound above baseline after PS cessation | Dependency 1.5 to 2.5; Reversibility 1.1 to 2.0 | 5.8 / 10 👍 Worth trying |
| Clean non-bovine DHA-rich PS becomes available and shows strong safety plus cognitive replication | Efficacy 3.2 to 3.8; Evidence 3.5 to 4.0 | 7.4 / 10 💪 Strong recommend |
Key Evidence Sources
- Duan et al. 2025 - Effects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment, Journal of Affective Disorders. 190 randomized MCI patients; positive cognitive findings from a multi-ingredient formula, so PS-specific attribution is not separable.
- Friling et al. 2025 - The cognitive effects of supplementation with sunflower phosphatidyl serine in healthy children aged 8 to 12 years, Nutrition Journal. 209 randomized healthy children; no total-cohort primary or secondary outcome differences; subgroup signal for lower baseline cognitive performance.
- Shen et al. 2026 - The effect of phosphatidylserine on behavioral problems in children with attention deficit hyperactivity disorder, Frontiers in Psychiatry. Open-label randomized comparison in 56 children; PS did not significantly improve core ADHD symptoms while atomoxetine did.
- Guo et al. 2024 - Phosphatidylserine: A Novel Target for Ischemic Stroke Treatment, Biomolecules. Narrative/translational review of PS biology in ischemic stroke; mechanism source, not oral supplement efficacy evidence.
- Crook et al. 1991 - Effects of phosphatidylserine in age-associated memory impairment, Neurology. 149 AAMI patients; bovine cortex PS 300 mg/day for 12 weeks improved learning and memory-related performance versus placebo.
- Cenacchi et al. 1993 - Cognitive decline in the elderly: double-blind placebo-controlled multicenter trial of phosphatidylserine, Aging. 494 older adults; 300 mg/day for 6 months improved behavioral and cognitive measures with good tolerability.
- Maggioni et al. 1990 - Effects of phosphatidylserine therapy in geriatric patients with depressive disorders, Acta Psychiatrica Scandinavica. Small elderly female sample; mood, memory, and behavior signal. v0 sample-size language was corrected downward.
- Monteleone et al. 1992 - Blunting by chronic phosphatidylserine administration of stress-induced HPA-axis activation in healthy men, European Journal of Clinical Pharmacology. 9 healthy men; chronic bovine PS 800 mg/day blunted ACTH and cortisol responses to exercise stress.
- Hellhammer et al. 2004 - Effects of soy lecithin phosphatidic acid and phosphatidylserine complex on endocrine and psychological responses to mental stress, Stress. Mental-stress study using PAS complex; supports stress-reactivity framing but not PS-alone attribution.
- Starks et al. 2008 - The effects of phosphatidylserine on endocrine response to moderate intensity exercise, Journal of the International Society of Sports Nutrition. 10 healthy men crossover; 600 mg/day for 10 days reduced peak cortisol and cortisol exposure during exercise stress.
- Jorissen et al. 2001 - The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment, Nutritional Neuroscience. 120 older adults; 300 or 600 mg/day soy-derived PS showed no significant cognitive benefit versus placebo.
- Kato-Kataoka et al. 2010 - Soybean-derived phosphatidylserine improves memory function of elderly Japanese subjects with memory complaints, Journal of Clinical Biochemistry and Nutrition. 78 older adults; no broad between-group signal, but memory improvements in lower-baseline subgroup.
- Vakhapova et al. 2010 - Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints, Dementia and Geriatric Cognitive Disorders. 157 older adults; PS-DHA improved verbal immediate recall and subgroup memory outcomes.
- Vakhapova et al. 2011 - Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly, BMC Neurology. Safety extension and tolerability evidence for PS-DHA in elderly participants with memory complaints.
- Manor et al. 2012 - PS-omega-3 in children with ADHD symptoms, European Psychiatry. 200 children; double-blind phase plus extension; benefits concentrated in selected scales and subgroups.
- Hirayama et al. 2014 - Phosphatidylserine administration on memory and ADHD symptoms, Journal of Human Nutrition and Dietetics. Small pediatric RCT; PS improved memory and inattention-related outcomes.
- Lee et al. 2021 - Phosphatidylserine for pediatric ADHD: systematic review and meta-analysis, Journal of Alternative and Complementary Medicine. Four studies narrative review; three RCTs in meta-analysis; inattention signal, overall evidence quality low.
- Kim et al. 2014 - Phosphatidylserine in the brain: metabolism and function, Progress in Lipid Research. Mechanistic review of brain PS metabolism, DHA-rich PS, synaptic function, and membrane signaling.
- Ma et al. 2022 - Phosphatidylserine, inflammation, and central nervous system diseases, Frontiers in Aging Neuroscience. Mechanistic CNS review; useful for neuroinflammation context, not oral supplement efficacy.
- FDA - Qualified Health Claims Letters of Enforcement Discretion. Official source for phosphatidylserine cognitive-function qualified health claim letters.
- EFSA Panel NDA 2011 - Scientific opinion on phosphatidylserine and cognitive function. EFSA did not approve the soy-derived PS cognition health claim due to insufficient cause-and-effect evidence.
- Alzheimer's Association - Alternative Treatments. Cautious society position: early bovine-source promise, soy-source uncertainty, experts do not currently recommend PS for Alzheimer's disease.
- WADA - Prohibited List. Phosphatidylserine is not listed as a named prohibited substance; supplement contamination risk still applies.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Friling 2025, Duan 2025, Shen 2026, Jorissen 2001, Kato-Kataoka 2010, Vakhapova 2010, Lee 2021, Starks 2008
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Crook 1991, Cenacchi 1993, Maggioni 1990, FDA 2003 qualified claim
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for Phosphatidylserine
All lenses point in the same direction but with different strength. Modern trials show targeted benefit in older adults, stress physiology, and pediatric inattention, while also showing null results in healthier or broader cohorts. Historical evidence explains why early bovine cortex results may not fully transfer to modern soy or sunflower PS. Traditional food patterns support phospholipid intake, not high-dose isolated PS. The honest synthesis: phosphatidylserine is useful when baseline need exists, but it is not a universal brain supplement.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Cortisol AM Baseline (pre-protocol) During | Expected Down
- ALT During | Expected Stable
Pulse Dimensions to Watch
- Calm During | Expected Up | Primary
- Sleep During | Expected Up | Secondary
- Drive During | Expected Up | Secondary
Subjective Signals (Daily Voice Card)
- Stress Reactivity Scale 1-5 | During | Expected Down
- Memory Recall Scale 1-5 | During | Expected Up
- Sleep Quality Scale 1-5 | During | Expected Up
Red Flags: Stop and Consult
- Excess sedation
- New insomnia or vivid dreams
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.215 − 0.519 = 1.696
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.696 / 5) × 5 = 6.7 / 10
